United States:
Incentives To Repurpose Existing Drugs For Orphan Indications
To print this article, all you need is to be registered or login on Mondaq.com.
Fabian M. Koenigbauer and
Annette K. Kwok published "Incentives to Repurpose Existing Drugs for Orphan
Indications" in ACS Medicinal Chemistry Letters
(DOI: 10.1021/acsmedchemlett.5b00276) on July 23, 2015. This
article discusses the Orphan Drug Act and its success in providing
incentives to find cures for orphan diseases, as well as the 21st
Century Cures Act and the Orphan Product Extension Now Accelerating
Cures and Treatment Act of 2015, pending bills created to provide
additional incentives to innovators to repurpose existing drugs for
the treatment of orphan diseases.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...